论文信息 - Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast. - 字舞流文

Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.

C. Curiel-Lewandrowski | Kevin Cavanaugh | I. Krase

[1] A. Qureshi,et al. Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center. , 2014, JAMA dermatology.

[2] A. Palfreeman,et al. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast , 2013, Drug design, development and therapy.

[3] D. Symmons,et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta‐analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data , 2011, Pharmacoepidemiology and drug safety.

[4] Sigrid Karrer,et al. Pityriasis Rubra Pilaris , 2010, American journal of clinical dermatology.

[5] B. Zelger,et al. Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. , 2008, Journal of the American Academy of Dermatology.